Equities analysts expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to announce $0.21 earnings per share for the current quarter, according to Zacks. Four analysts have made estimates for Amphastar Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.28 and the lowest estimate coming in at $0.17. Amphastar Pharmaceuticals reported earnings per share of $0.16 in the same quarter last year, which indicates a positive year over year growth rate of 31.3%. The business is scheduled to announce its next quarterly earnings results on Thursday, August 5th.
According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full-year earnings of $1.02 per share for the current financial year, with EPS estimates ranging from $0.90 to $1.25. For the next fiscal year, analysts expect that the company will report earnings of $1.41 per share, with EPS estimates ranging from $1.16 to $1.89. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, May 6th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.08. Amphastar Pharmaceuticals had a return on equity of 7.45% and a net margin of 0.68%. The company had revenue of $103.02 million for the quarter, compared to the consensus estimate of $97.12 million.
AMPH stock opened at $20.88 on Tuesday. Amphastar Pharmaceuticals has a fifty-two week low of $16.91 and a fifty-two week high of $22.69. The firm has a 50-day moving average price of $18.95. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.60 and a current ratio of 2.36. The company has a market capitalization of $994.51 million, a P/E ratio of 29.87 and a beta of 0.72.
In related news, EVP Yakob Liawatidewi sold 10,000 shares of the stock in a transaction dated Tuesday, May 11th. The stock was sold at an average price of $19.06, for a total transaction of $190,600.00. Following the completion of the sale, the executive vice president now owns 71,351 shares in the company, valued at $1,359,950.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard K. Prins sold 15,827 shares of the stock in a transaction dated Tuesday, May 11th. The stock was sold at an average price of $18.90, for a total value of $299,130.30. Following the sale, the director now owns 54,987 shares of the company’s stock, valued at approximately $1,039,254.30. The disclosure for this sale can be found here. Insiders sold 111,361 shares of company stock worth $2,136,476 in the last ninety days. Corporate insiders own 28.40% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. grew its position in shares of Amphastar Pharmaceuticals by 8.4% during the fourth quarter. Victory Capital Management Inc. now owns 13,572 shares of the company’s stock worth $273,000 after purchasing an additional 1,050 shares in the last quarter. Alliancebernstein L.P. grew its holdings in Amphastar Pharmaceuticals by 1.2% during the 4th quarter. Alliancebernstein L.P. now owns 89,883 shares of the company’s stock valued at $1,808,000 after buying an additional 1,073 shares in the last quarter. Panagora Asset Management Inc. grew its holdings in Amphastar Pharmaceuticals by 16.1% during the 4th quarter. Panagora Asset Management Inc. now owns 9,192 shares of the company’s stock valued at $185,000 after buying an additional 1,276 shares in the last quarter. Captrust Financial Advisors grew its holdings in Amphastar Pharmaceuticals by 1,889.3% during the 1st quarter. Captrust Financial Advisors now owns 1,492 shares of the company’s stock valued at $27,000 after buying an additional 1,417 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in Amphastar Pharmaceuticals by 2.0% during the 1st quarter. Rhumbline Advisers now owns 84,256 shares of the company’s stock valued at $1,544,000 after buying an additional 1,675 shares in the last quarter. Hedge funds and other institutional investors own 54.67% of the company’s stock.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.
Recommended Story: How are Outstanding Shares Different from Authorized Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.